# US 2012/0252029 A1 · Simultaneous quantitative multiple primer detection of clostridium difficile

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252029 A1
- Document ID: US20120252029A1
- Status: Published application
- Kind: A1
- Application number: 13/384,446
- Filed: 2010-07-15
- Published: 2012-10-04
- Earliest claimed: 2009-07-17
- Assignees: Brown University
- Inventors: Aartik Sarma; Anubhav Tripathi; Leonard Mermel; Aleksey Novikov; Leah Seward; Jennifer Fieber
- Web page: https://patentgrep.com/patent/US20120252029A1

## CPC

- C12Q 1/689: for bacteria
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This invention comprises a multiplex-capable oligonucleotide which is capable of hybridizing to at least one of the C. difficile tcdB, tcdC, or cdtB genes, wherein, wherein said primer consists of a sequence selected from the group consisting of SEQ ID NOS: 1 through 9, or a sequence that exhibits no more than one substitution of a base to a sequence selected from the group consisting of SEQ ID NOS: 1 through 9 and method for polymerase chain reaction (PCR) determining of the presence of a toxigenic strain of C. difficile in a biological sample utilizing said probes.

## Claims

### Claim 1

A multiplex-capable oligonucleotide which is capable of hybridizing to at least one of the C. difficile tcdB, tcdC, or cdtB genes, wherein, wherein said oligonucleotide consists of a sequence selected from the group consisting of SEQ ID NOS: 1 through 9, or a sequence that exhibits no more than one substitution of a base to a sequence selected from the group consisting of SEQ ID NOS: 1 through 9.

### Claim 2 (depends on 1)

The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 1.

### Claim 3 (depends on 1)

The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 2.

### Claim 4 (depends on 1)

The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 3.

### Claim 5 (depends on 1)

The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 4.

### Claim 6 (depends on 1)

The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 5.

### Claim 7 (depends on 1)

The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 6.

### Claim 8 (depends on 1)

The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 7.

### Claim 9 (depends on 1)

The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 8.

### Claim 10 (depends on 1)

The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 9.

### Claim 11 (depends on 1)

A method for polymerase chain reaction (PCR) determining of the presence of a toxigenic strain of C. difficile in a biological sample, comprising:
a. simultaneously contacting said biological sample with at least three pair of multiplex-capable oligonucleotides each of claim 1;
b. amplifying target nucleic acid from said biological; and,
c. detecting the presence or amount of an amplified product(s) as an indicator of the presence of said toxigenic strain of C. difficile in said biological sample.

### Claim 12 (depends on 11)

The method of claim 11, wherein said biological sample is selected from the group consisting of stool, sputum, peripheral blood, plasma, serum, lymph nodes, respiratory tissue and exudates.

### Claim 13 (depends on 12)

The method of claim 12, wherein said biological sample is a stool sample.

### Claim 14 (depends on 11)

The method of claim 11, wherein said PCR is selected from the group consisting of AFLP, Alu-PCR, Asymmetric PCR Colony PCR, DD-PCR, Degenerate PCR, Hot-start PCR, In situ PCR, Inverse PCR Long-PCR, Multiplex PCR, Nested PCR, PCR-ELISA, PCR-RFLP, PCR-single strand conformation polymorphism (PCR-SSCP), quantitative competitive PCR (QC-PCR), rapid amplification of cDNA ends-PCR(RACE-PCR), Random Amplification of Polymorphic DNA-PCR(RAPD-PCR), Real-Time PCR, Repetitive extragenic palindromic-PCR (Rep-PCR), reverse transcriptase PCR(RT-PCR), TAIL-PCR, Touchdown PCR and Vectorette PCR.

### Claim 15 (depends on 14)

The method of claim 14, wherein said PCR is quantitative real-time PCR (QRT-PCR).
